Arrowhead Pharmaceuticals reported positive Phase 1/2a interim data for its experimental RNA interference drug ARO-MAPT, showing up to a 73% average reduction in cerebrospinal fluid tau protein among healthy volunteers. Delivered via subcutaneous injection across the blood-brain barrier, ARO-MAPT demonstrated safe, sustained tau silencing that supports quarterly dosing and offers potential advantages over existing amyloid-targeting drugs and spinal anti-tau therapies.
Phase 1/2a trial results for ARO-MAPT
- ▪Healthy volunteers receiving subcutaneous ARO-MAPT doses of 2.1 mg/kg and 6.4 mg/kg on days 1, 8, and 15 in the Phase 1/2a trial achieved average cerebrospinal fluid tau reductions of 40% and 69% respectively at day 105.
- ▪Arrowhead Pharmaceuticals reported that ARO-MAPT was generally well tolerated in healthy volunteers, with no serious adverse events, deaths, or toxicity-related study dropouts, and mild reported side effects including injection site reactions, vessel puncture bruising, respiratory infections, and headaches.
- ▪In an ongoing Phase 1/2a trial in healthy volunteers, Arrowhead Pharmaceuticals' experimental RNA interference therapeutic ARO-MAPT administered via subcutaneous injection reduced cerebrospinal fluid total tau protein by an average of 73% at day 105 in the highest dose cohort receiving 12.8 mg/kg on days 1 and 15, with maximum individual reduction reaching 85%.
ARO-MAPT dosing and trial design
- ▪Arrowhead Pharmaceuticals enrolled about 64 healthy volunteers across three dose levels in the initial portion of its Phase 1/2a ARO-MAPT trial.
- ▪The 73% mean reduction in cerebrospinal fluid tau observed 90 days after the final dose in Arrowhead Pharmaceuticals' Phase 1/2a study supports potential ARO-MAPT dosing once every three months or less frequently.
Blood-brain barrier drug delivery platform
- ▪Stifel analyst James Condulis noted in an October 14, 2026 report that Arrowhead Pharmaceuticals' subcutaneous drug delivery across the blood-brain barrier looks compelling and arguably better than competing central nervous system delivery platforms.
- ▪Arrowhead Pharmaceuticals stated that the Phase 1/2a ARO-MAPT trial results provide clinical validation for its drug platform to deliver subcutaneous RNA-modulating therapeutics across the blood-brain barrier into the central nervous system.
Evaluating ARO-MAPT in tauopathies
- ▪ARO-MAPT is designed to silence expression of the microtubule-associated protein tau (MAPT) gene in the central nervous system, targeting pathological tau protein aggregation implicated in Alzheimer's disease, frontotemporal dementia, and progressive supranuclear palsy.
- ▪Arrowhead Pharmaceuticals noted that ARO-MAPT's effects on brain tau protein tangles, cognition, function, and disease progression must still be investigated in patients with Alzheimer's disease and other tauopathies.
Planned trial expansion into patient populations
- ▪Arrowhead Pharmaceuticals is in discussions with health regulators to initiate clinical trials evaluating ARO-MAPT in patients with MAPT-associated frontotemporal dementia and progressive supranuclear palsy.
- ▪The Phase 1/2a trial of ARO-MAPT aims to enroll 112 total participants, expanding from healthy volunteers into patients with early Alzheimer's disease receiving up to five subcutaneous injections, with further data updates expected in 2027.
Comparisons with Biogen's diranersen
- ▪Jefferies analysts cautioned against direct head-to-head comparisons between ARO-MAPT and diranersen, citing differences in dosing protocols and trial populations as diranersen was evaluated in mild Alzheimer's patients while interim ARO-MAPT data reflects healthy volunteers.
- ▪Stifel analysts stated that Arrowhead Pharmaceuticals' subcutaneously injected ARO-MAPT achieved higher cerebrospinal fluid tau reduction than Biogen's diranersen (BIIB080), an anti-tau antisense oligonucleotide delivered via direct intrathecal spinal injection that reduced tau by 30% to 56% in Phase 1b trials.
- ▪Biogen announced in May 2026 that its anti-tau drug diranersen failed its primary cognitive dose-response endpoint in the Phase 2 CELIA trial, though Biogen plans to advance the drug to registrational trials based on observed reductions in tau pathology.
Amyloid-targeting Alzheimer's treatments
- ▪Amyloid-targeting Alzheimer's treatments Leqembi and Kisunla show modest clinical benefits, carry safety warnings against prescribing to patients on blood thinners, and fail to halt or reverse cognitive decline despite removing amyloid lesions.
- ▪FDA-approved Alzheimer's monoclonal antibodies introduced in the early 2020s, including Leqembi and Kisunla, target brain amyloid beta protein accumulation rather than tau protein tangles.
Story comments
Loading comments…